Article Information
History
- November 8, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Isabell Wagenhäuser1,
- Julia Reusch2,
- Alexander Gabel, PhD1,
- Lukas B. Krone, MD PhD3,
- Oliver Kurzai, MD4,
- Nils Petri, MD2 and
- Manuel Krone, MD, MScPH1,*
- 1Infection Control and Antimicrobial Stewardship Unit, University Hospital Wuerzburg, Wuerzburg, Germany
- 2Department of Internal Medicine I, University Hospital Wuerzburg, Wuerzburg, Germany
- 3Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK
- 4Institute for Hygiene and Microbiology, University of Wuerzburg, Wuerzburg, Germany
- ↵*Corresponding author: Manuel Krone, Infection Control and Antimicrobial Stewardship Unit, University Hospital Wuerzburg, Josef-Schneider-Str. 2 / E1, 97080 Wuerzburg, Germany, krone_m{at}ukw.de, +49-931-201-46710
Posted November 08, 2022.
Bivalent BNT162b2mRNA original/Omicron BA.4-5 booster vaccination: adverse reactions and inability to work compared to the monovalent COVID-19 booster
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
4
Blogs/Media
Author Videos